BioNTech
NEWS
NEUVOGEN’s official strategy revolves around covering the entire immune system so that the tumor cannot perform an “immune escape”. Past immune priming efforts have fallen short because they focus on only a handful of important targets that some tumor cells may not express, thereby allowing them to escape the therapy’s boundaries.
Pfizer and BioNTech announced that their COVID-19 vaccine was probably just as effective against the variant strain of the virus, B.1.1.7, found in the U.K.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
Publicly-traded companies that have been heavily involved in developing therapies and vaccines for COVID-19 have seen significant spikes in their stock prices over the past 10 months, including Germany’s BioNTech, which has surged 187% in one year.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for January 12, 2021.
News, much of it good, keeps coming in about the efficacy of the various COVID-19 vaccines. Here’s a look.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Yesterday it was reported that the two companies were working to make more of their vaccine than the 1.3 billion it promised to manufacture in 2021.
In a December 8, 2020 meeting with U.K. scientists and public health experts, it was announced that there was a growing new strain of the SARS-CoV-2 virus that causes COVID-19.
JOBS
IN THE PRESS